Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HTR1A | P08908 | 5/20 | 0.58 |
| ▸ | HTR7 | P34969 | 5/20 | 0.58 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398060 | 0.88 | ALDH1A1 (0.77) | PARP1ALDH1A1LMNA | |
| SCHEMBL11788348 | 0.80 | ALDH1A1 (0.68) | ALDH1A1KDM4ELMNATDP1 | |
| Hydrochloric Acid SCHEMBL11788201 | 0.79 | ALDH1A1 (0.67) | ALDH1A1KDM4ELMNATDP1 | |
| SCHEMBL31060680 | 0.78 | PARP1 (1.00) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL6796582 | 0.74 | GAA (0.76) | PARP1HTR1AHTR7PARP2MDM2 | |
| SCHEMBL6795915 | 0.74 | PARP1 (0.70) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL12946412 | 0.74 | PARP1 (0.67) | PARP1HTR1AHTR7PARP2KDM4E | |
| SCHEMBL6795601 | 0.74 | PARP1 (0.70) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL6795086 | 0.74 | PARP1 (0.87) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL6796265 | 0.74 | PARP1 (0.70) | PARP1HTR1AHTR7PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1355888-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002048117-A1 | QUINAZOLINONE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | PARP1 1/4885ALDH1A1 201/4885HTR1A 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.